The Claim
CYP1B1 deficiency disrupts redox homeostasis in pathogenic Th17 cells by reducing glutathione synthetase expression, resulting in elevated reactive oxygen species and mitochondrial dysfunction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When the CYP1B1 gene is not functional, pathogenic Th17 cells experience a drop in glutathione synthetase, which leads to higher levels of reactive oxygen species and impaired mitochondrial function.
See the scientific wording
CYP1B1 deficiency disrupts redox homeostasis in pathogenic Th17 cells by reducing glutathione synthetase, leading to increased reactive oxygen species and mitochondrial dysfunction.
When CYP1B1 is missing, immune cells called pathogenic Th17 cells cannot make enough of a key antioxidant molecule. This causes harmful reactive oxygen species to build up inside the cells, which damages their energy-producing structures called mitochondria. As a result, these immune cells cannot survive or function properly.
What the research says
1 studyWhen the CYP1B1 gene is missing, immune cells called Th17 can’t make enough of a protective antioxidant, so harmful molecules build up and damage their energy factories (mitochondria). The study shows fixing this antioxidant fixes the damage.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.